



OPEN ACCESS

APPROVED BY
Pathology and Oncology Research
Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Peter Batar,
✉ pbatar@med.unideb.hu

RECEIVED 06 March 2024
ACCEPTED 07 March 2024
PUBLISHED 21 March 2024

CITATION
Batar P, Alizadeh H, Rokszin G,
Abonyi-Toth Z and Demeter J (2024),
Corrigendum: Comorbidities and
outcomes of patients with chronic
myeloid leukemia treated with tyrosine
kinase inhibitors: a real-world,
nationwide, retrospective study
from Hungary.
Pathol. Oncol. Res. 30:1611758.
doi: 10.3389/pore.2024.1611758

COPYRIGHT
© 2024 Batar, Alizadeh, Rokszin,
Abonyi-Toth and Demeter. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Peter Batar^{1*}, Hussain Alizadeh², Gyorgy Rokszin³,
Zsolt Abonyi-Toth^{3,4} and Judit Demeter⁵

¹Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ²1st Department of Medicine, Division of Haematology, Clinical Center, Medical School, University of Pecs, Pecs, Hungary, ³RxTarget Ltd., Szolnok, Hungary, ⁴Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary, ⁵Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

KEYWORDS

chronic myeloid leukemia, real-world evidence, tyrosine kinase inhibitors, treatment outcome, overall survival

A Corrigendum on
Comorbidities and outcomes of patients with chronic myeloid leukemia
treated with tyrosine kinase inhibitors: a real-world, nationwide,
retrospective study from Hungary

by Batar P, Alizadeh H, Rokszin G, Abonyi-Toth Z and Demeter J (2024). *Pathol. Oncol. Res.* 30: 1611497. doi: 10.3389/pore.2024.1611497

In the published article, there was an error in the **Funding** statement. It originally stated:

“The authors declare that this study received funding from Pfizer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”

The **Funding** statement has now been removed.

In the published article, there was an error in the **Conflict of interest** Statement. It originally stated:

“Authors GR and ZA-T were employed by RxTarget Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The correct **Conflict of interest** statement appears below.

“GR and ZA-T are employees of RxTarget Ltd., which was a paid contractor to Pfizer in connection with the development of this manuscript and was responsible for data curation and statistical analysis. This study was sponsored by Pfizer. Medical writing support was provided by Zsófia Barcza at Syntesia Medical Communications Ltd.

and was funded by Pfizer. The funder had the following involvement in the study: administrative support and review regarding study design, statistical analysis, and manuscript development.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.